This article presents current best knowledge to assess the projected outcomes benefit of adding multi-modality surveillance imaging to standard follow-up care for breast cancer patients at high risk (>30%) for developing future metastases. This analysis is motivated by recent preliminary clinical studies that have suggested that augmenting systemic treatment of early-stage metastases with targeted surgery and/ or radiosurgery achieves significant overall survival and disease-free survival benefit.
| INTRODUCTION
Network guidelines for asymptomatic breast cancer survivors omit proactive imaging for the early detection of metastatic disease, regardless of a patient's metastatic risk. 4 These guidelines are based on studies conducted in Italy from 1985-1993 that involved breast cancer survivors who underwent repeat chest x-rays for detection of MBC with additional systemic therapy as the only treatment option. 5, 6 Both studies concluded that the imaging and treatment options of the day did not prolong the 5-year overall survival (OS)
rate. Under the current standard follow-up care guidelines, 85% of patients with MBC are diagnosed because of outward clinical symptoms, 7 typically with multiple tumor masses afflicting multiple organs.
Correspondingly, the OS and disease-free survival (DFS) rates at 5 years for MBC remain discouraging at approximately 20% and 2%, respectively. 7, 8 Oligometastases is the state in which a patient has only a few (typically six or fewer) small (typically 5 cm or less) observable metastases that are amenable to surgery or stereotactic body radiation therapy (SBRT). Numerous national and international studies have achieved better than anticipated OS and DFS rates for oligometastatic breast cancer (oligoMBC) treated using combined systemic and local therapy. 9, 10 However, none of these were conducted in a controlled clinical trial setting, although a large national trial is currently underway. 17 Notably, two controlled clinical trials of combined therapy for metastatic lung cancer were stopped early due to a threefold improvement in the 1-year median progression-free survival rate. 18, 19 Under the ideal imaging protocol, when a suspicious lesion is detected, the next follow-up scan would occur prior to the lesions exceeding 15 mm in diameter-within the range at which 100% local control for MBC has been documented. 15 The detection limits of 3-dimensional (3D) imaging, the variable growth rates of metastases, the burden to the patient caused by surveillance imaging and cumulative radiation exposure, and the overall cost of all impact selection of the optimal scan interval. Because MBC has long been considered a terminal diagnosis, assessment of MBC patterns of presentation has not been considered worthwhile; thus, many basic features of metastatic progression, such as metastatic tumor growth rates and number of metastases at first diagnosis, remain unknown. By fitting model parameters to statistics for the duration of survival, Coumans et al 21 deduced that the average doubling time for distant breast cancer metastases to any site is 1.7 months. Although modern x-ray CT imaging can identify 2-3 mm lesions in the lung, radiological assessment of specific features, such as border and texture, typically requires lesions to be 5 mm or larger. For the purposes of our analysis, we assumed that no lesion larger than 4 mm would be missed on a routine surveillance scan. Table 1 outlines tumor size at 6, 9, and 12-month scan intervals. It shows that 9 months is the longest interval at which a missed 4-mm lesion would remain <15 mm in diameter after two subsequent scans.
| Determinants of surveillance imaging initiation and duration
The time to manifestation of clinical symptoms from metastases varies by primary tumor subtype 22 and size. 21 The time to detection of the first metastatic site in the clinic averages 5.3 years, 14 ; however, 19% of these patients were diagnosed incidentally or through screening. Thus, the median size for symptomatic lesions is somewhat larger. PET imaging is typically sensitive to masses of 15 mm or larger, with a minimum 7-mm detectability under ideal conditions. 24 The minimum reliable detection for the brain and liver when using modern CT or MRI is 3-7 mm. 25 Thus, the time to first detection using modern imaging should precede the time to first clinical symptoms by at least 2 years for a typical tumor (with a doubling time of 1.7 months 21 ). This suggests that the majority of patients will develop imaging-detectable metastases within 3.5 years of diagnosis of the primary tumor, with the highest yearly frequency of detections in each of the first 2 years. Thus, based on current best knowledge, the optimal imaging protocol would entail an initial scan at 9 months after the primary tumor was treated, with repeated 9-month follow-up scans out to 45 months (3.75 years), for a total of five follow-up scans.
| Assessment of relative cancer risk of surveillance imaging
Radiation exposure from the repeat PET/CT scans used for surveillance imaging can increase a patient's risk of developing new cancers. A typical whole-body PET scan produces an estimated 6.23-mSv exposure, 26 and a diagnostic quality whole-body CT scan (from the C3 vertebra in the neck to mid-thigh) results in approximately 12-mSv exposure. 27 The exact exposure level is impacted by the size and composition of the patient and variances in the imaging equipment. The optimal MBC surveillance imaging protocol would involve five PET/CT scans over 3.75 years, resulting in 91.15 mSv to each patient. For comparison, the average yearly radiation exposure from background sources is 3.1 mSv, and the 5-year occupational dose limit for health care workers is 100 mSv. 28 For a 40-year-old woman, the lifetime attributable risk (LAR) of cancer incidence from a onetime, 91-mSv exposure is 0.78%, 29 whereas for a 30-year-old woman (ie, the youngest subjects expected in a breast metastasis surveillance study), the LAR is 1.6%. The increased lifetime risk of cancer mortality for a 45-year-old woman exposed to 91 mSv is 0.074%.
This calculation assumes a linear dependency of mortality on dose,
T A B L E 1 Size of a nodule (in mm) as a function of scan interval (in months; along columns) and scan number (along rows) for a metastasis of diameter 4 mm at time zero and a doubling time of The key feature is that the 9-mo scan interval is the longest in which an initially missed 4-mm nodule would remain less than 15 mm at the 2nd follow-up scan.
with a single exposure of 100 mSv causing 0.081% excess lifetime cancer mortality. 30 If 1351 patients were enrolled in the proposed imaging surveillance study, one patient would be expected to die sometime during her lifetime from cancer induced by the five PET/ CT scans. 10 .7% for non-oligoMBC, 7 and 20% for overall MBC. 7 Among those who develop metastases, the prevalence of oligoMBC is assumed to be 22%. 7 A conservative estimate of 60% oligoMBC incidence under imaging is applied. Using these values and under standard of care follow-up, 76.0% of high-risk women would be surviving at 5 years:
(70% without MBC all surviving, plus 20% survival in the remaining 30%). Within the surveillance imaging protocol, the survival rate for high-risk women would be expected to increase to 80.0%:
(70% without MBC all surviving, plus 48.5% survival in the 60% of the remaining 30% with oligoMBC, plus 10.7% survival in the remaining patients). Thus, a 4.0% benefit in OS at 5 years is projected to occur when surveillance imaging is added to current follow-up care for this patient population. For every 25 patients receiving surveillance imaging, one additional patient will achieve long-term survival.
| Radiation risk-benefit assessment
Surveillance imaging for early detection and treatment of MBC in patients with a 30% risk for developing future metastases using the proposed protocol creates a 4% 5-year OS benefit vs a 0.074% lifetime cancer mortality rate, resulting in a 54:1 benefitto-risk ratio.
| DISCUSSION

| Application to patients at lower risk
As a patient's likelihood for developing MBC decreases, the projected benefit of surveillance imaging likewise decreases. The treatment benefit as a function of MBC probability, p, is given by
The treatment benefit is negated by the imaging-related cancer mortality (0.074%) at a value of 0.0055 (0.55%) for a patient's proba- 
| Limitations of radiation risk assessment
The LAR of cancer incidence established in the BEIR V report 29 for the study patients is likely higher than that described for the healthy adult population, the expected 54:1 survival benefit-to-risk ratio for the high-risk population is unlikely to be negated with a more accurate appreciation of the true risks to these patients.
| Potential for superior outcomes under surveillance imaging
While all prior studies assessing the efficacy of combined therapy for MBC showed better-than-expected outcomes, none were in the context of a randomized prospective trial; thus, more definitive OS data are needed for oligoMBC. In addition, there is potential for a lead-time bias of 2-3 years in the survival outcomes, although in one study the 4-year OS rate of 54% dropped only to 47% at 6 years, 15 suggesting that lead-time bias does not explain all of the reported gains over historical controls. However, none of the prior MBC studies utilized surveillance imaging to identify MBC in its most favorable state; consequently, larger survival gains may be possible when proactive imaging is provided.
| Consideration of scan and treatment costs
A comprehensive cost-benefit analysis is beyond the scope of this paper but would include an 8+year follow-up assessment of qualityadjusted life years (QALY) and consideration of costs of SBRT for O'DELL ET AL.
